Summary
The AI-generated claims mostly concern dietary calcium/magnesium supplementation and are not supported by the FDA-approved Magnesium Sulfate in Water for Injection labeling. The label addresses obstetric use, dosing, contraindications, warnings, and adverse effects for magnesium sulfate in a preeclampsia/eclampsia context, which is not reflected in the extracted claims.
Category Scores
Accurate Statements
Unsupported Statements
Magnesium and calcium supplements are commonly taken together and generally safe for most people, as they work in balance for bone health, muscle function, and nerve signaling.
Label describes magnesium sulfate for preeclampsia/eclampsia; no general supplement guidance for bone health or combined calcium/magnesium safety.
The body regulates both minerals through absorption in the intestines, and pairing them mimics dietary sources like dairy or leafy greens.
Label does not provide information on intestinal absorption regulation or dietary mimicry of supplementation.
Aim for a 2:1 calcium-to-magnesium ratio (e.g., 1000mg calcium with 500mg magnesium daily) to optimize uptake, based on NIH guidelines for adults.
Label does not cite NIH guidelines or ratio-based recommendations for calcium/magnesium supplementation.
Calcium: 1000-1200mg for adults (from food plus supplements if needed).
Label does not specify calcium intake recommendations for adults.
Magnesium: 310-420mg for adults.
Label does not specify general magnesium intake recommendations for adults.
Take them with meals to boost absorption.
Label provides no guidance on taking calcium/magnesium with meals.
Split doses if over 500mg calcium to avoid stomach upset.
Label does not address dosing strategies for calcium/magnesium supplements.
A common combo is 500mg calcium citrate with 250mg magnesium glycinate.
No formulation-specific supplement recommendations in label.
In high doses, magnesium can compete with calcium for absorption in the gut, potentially reducing calcium uptake by 10-20% if ratios exceed 1:1 magnesium-to-calcium.
Label contains no comparative absorption data for calcium/magnesium supplements.
Excess calcium can do the same to magnesium.
Label does not discuss mutual interference of minerals in this context.
Stick to balanced ratios and space doses 2 hours apart if concerned, though studies show no major issues in standard use.
No guidance on dosing spacing for calcium/magnesium in the label.
Calcium: Citrate or carbonate.
Label does not cover calcium salt forms for dietary supplements.
Calcium citrate absorbs without food; carbonate is cheaper but needs acid.
No discussion of calcium salt absorption with or without food in the label.
Magnesium: Glycinate or citrate.
Label does not discuss magnesium salt forms for dietary supplements.
Magnesium glycinate or citrate: Gentle on stomach, high bioavailability; avoids laxative effect of oxide.
No guidance on specific magnesium salts and tolerability in the label.
Avoid magnesium oxide with calcium carbonate, as both rely on stomach acid and may underperform.
Label does not provide guidance on combining specific magnesium and calcium salts.
Magnesium oxide has a laxative effect.
No discussion of magnesium oxide laxative effects in the label.
Calcium carbonate relies on stomach acid.
Label does not discuss calcium salt-specific digestion or reliance on gastric acid for supplements.
Magnesium oxide relies on stomach acid.
Label does not discuss magnesium oxide in the context of dietary supplements.
Calcium carbonate and magnesium oxide may underperform when taken together.
No combination guidance for calcium carbonate and magnesium oxide in the label.
People with kidney disease: Impaired clearance risks hypermagnesemia or hypercalcemia.
Label warns about renal impairment for magnesium sulfate use and potential magnesium intoxication, but does not discuss hypercalcemia risk from supplements.
Those on antibiotics (e.g., tetracyclines) or bisphosphonates: Minerals bind to these drugs, reducing effectiveness—separate by 2-4 hours.
No drug interaction timing guidance for calcium/magnesium supplements in the label.
Pregnant or breastfeeding individuals: Consult a doctor for tailored dosing.
Label discusses pregnancy with magnesium sulfate but not general supplement dosing; no tailored dosing guidance for calcium/magnesium supplements.
No broad contraindications for healthy adults.
Label includes contraindication related to toxemia around delivery; not a broad statement for all healthy adults.
Get magnesium and calcium from foods first to minimize interaction risks.
No dietary-first guidance for supplements in the label.
Calcium-rich: Yogurt, kale, fortified almond milk.
No dietary sources guidance in the label.
Magnesium-rich: Almonds, spinach, black beans.
No dietary sources guidance in the label.
Supplements fill gaps, like for osteoporosis prevention, but whole foods provide cofactors like vitamin D for better synergy.
Label does not discuss supplementation strategy for osteoporosis or vitamin D synergy.
Contradictions
Important Omissions
Contraindications for renal impairment or hypermagnesemia risk with magnesium-containing products.
Importance:
High
Interactions with medications (e.g., tetracyclines, bisphosphonates) and guidance to separate dosing by time.
Importance:
High
Pediatric safety and dosing guidance; absence of age-appropriate recommendations or upper intake limits.
Importance:
High
Pregnancy and lactation-specific guidance for calcium/magnesium supplements beyond magnesium sulfate in preeclampsia/eclampsia.
Importance:
High
Dosing schedules, upper tolerable intake levels, and administration instructions (with/without food) for supplements.
Importance:
High
Adverse event monitoring and warning signs (e.g., hypercalcemia, renal stone risk with high calcium).
Importance:
Moderate
Formulation-specific guidance (salt forms) and their impact on absorption and tolerability.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claims address general supplementation outside the specific labeled indication; no direct patient-level safety guidance is provided by the label for these claims.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Needs Revision
Primary Issue
Substantial extrapolation beyond label content; claims are not supported by the Magnesium Sulfate in Water for Injection label and omit critical safety, interactions, and population-specific guidance.
Suggested Improvement
Limit claims to label-supported content; remove general supplement guidance; if discussing calcium/magnesium together, anchor statements to product-labeled indications (as applicable) and provide dosing, interactions, and population-specific considerations drawn from label or approved accompanying materials.